Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07331428 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study enrolls patients who have experienced local recurrence of nasopharyngeal carcinoma (NPC) with or without regional recurrence. The treatment regimen includes an induction phase with MRG003 at 2.0 mg/kg (D1) combined with Tislelizumab 200 mg (D1), administered weekly for 6 cycles. This is followed by maintenance therapy consisting of Capecitabine (650 mg/m², twice daily on days 1-21) in combination with Tislelizumab, continued for up to 1 year or until disease progression.
Trial Details
NCT Number NCT07331428
Lead Sponsor Fujian Cancer Hospital
Conditions
(from sponsor)		 Nasopharyngeal Carcinoma, Local Recurrence
Related terms Nasopharyngeal Carcinoma
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov